Lab-grown tumors predict treatment outcomes in landmark study
Researchers have grown tumors in the lab to accurately predict which drugs will work for people with bowel cancer—before they begin treatment.
Feb 2, 2024
0
73
Researchers have grown tumors in the lab to accurately predict which drugs will work for people with bowel cancer—before they begin treatment.
Feb 2, 2024
0
73
Recent data suggest that epigenetic therapies are likely to provide additional clinical benefit to cancer patients when rationally combined with immunotherapeutic drugs, according to a review published in Clinical Cancer ...
Sep 15, 2015
0
21
A symposium presented at the American Association for Cancer Research Annual Meeting 2016 offers updated results on the ongoing phase 1b clinical trial of anti-PDL1 immunotherapy atezolizumab in advanced stage colorectal ...
Apr 18, 2016
0
15
Colorectal cancer is the third most common cancer worldwide and the third-leading cause of cancer-related deaths. The main cause of death in patients with colorectal cancer is liver metastasis, with nearly 70% of patients ...
Apr 24, 2018
0
43
Patients with metastatic colorectal cancer harboring a subset of non-V600 mutations in the BRAF gene, known as class 3 BRAF mutations, were more likely to respond to anti-EGFR treatment.
Sep 12, 2019
0
4
Metastatic colorectal cancer patients tend to live longer when they respond to the first line of chemotherapy their doctors recommend. To better predict how patients will respond to chemotherapy drugs before they begin treatment, ...
Jun 17, 2015
0
10
Mayo Clinic Comprehensive Cancer Center researchers have identified key findings that can assist clinicians in predicting whether a patient with advanced colorectal cancer will benefit from immunotherapy. The study was published ...
Aug 31, 2023
0
1
(HealthDay)—There's more evidence that routine colonoscopy confers life-extending benefits.
Jun 19, 2013
0
0
A University of Colorado Cancer Center study published in the journal PLOS ONE shows that when colorectal cancer is targeted by the drug bevacizumab (Avastin), tumors may switch dependence from VEGF-A, which is targeted by ...
Oct 28, 2013
0
0
(HealthDay)—For patients with metastatic colorectal cancer who have resectable liver metastases, survival outcomes at five years do not differ significantly for treatment with laparoscopic versus open liver resection, according ...
Nov 17, 2020
0
1